GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

HYPR · Jun 30, 2026

Hyperfine, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-26-338015General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

339.01% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity0thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.77% · OPTIONAL · VALID

Operating cash generation93thOwn-history percentile · N=14
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-186.17% · OPTIONAL · VALID

Revenue growth70thOwn-history percentile · N=10
Evidence method

Yoy · gp.fundamentals.revenue

44.81% · CORE · VALID

Inventory pressure43thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

173.90% · OPTIONAL · VALID

Gross margin86thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.gross_margin

50.72% · CORE · VALID

Operating margin100thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.operating_margin

-216.93% · CORE · VALID

R&D intensity7thOwn-history percentile · N=14
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

99.00% · OPTIONAL · VALID

SBC intensity29thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

23.13% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20257/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
336.23%
Current
339.01%
Delta
2.78%
Capex Intensity Decreased
Previous
6.20%
Current
0.77%
Delta
-5.43%
Cash Generation Increased
Previous
-230.80%
Current
-186.17%
Delta
44.63%
Growth Decreased
Previous
82.64%
Current
44.81%
Delta
-37.83%
Inventory Pressure Increased
Previous
162.11%
Current
173.90%
Delta
11.79%
Margin Increased
Previous
50.70%
Current
50.72%
Delta
0.01%
Profitability Increased
Previous
-219.27%
Current
-216.93%
Delta
2.34%
R And D Intensity Increased
Previous
98.51%
Current
99.00%
Delta
0.49%
Sbc Intensity Increased
Previous
16.58%
Current
23.13%
Delta
6.55%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Compared To · Electromedical & Electrotherapeutic Apparatus peers →Transitioned To · HYPR Fundamental State →Transitioned To · HYPR BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · HYPR CAPEX_INTENSITY_DECREASED →Transitioned To · HYPR CASH_GENERATION_INCREASED →Transitioned To · HYPR GROWTH_DECREASED →Transitioned To · HYPR INVENTORY_PRESSURE_INCREASED →Transitioned To · HYPR MARGIN_INCREASED →Transitioned To · HYPR PROFITABILITY_INCREASED →Transitioned To · HYPR R_AND_D_INTENSITY_INCREASED →Transitioned To · HYPR SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.